A Decade in Leading BPH Care

How the UroLift™ System Continues to Deliver Consistent Durability With a Superior Patient Experience

It has been more than 10 years since the UroLift™ System first came to market, and today it is the #1 minimally invasive treatment for benign prostatic hyperplasia (BPH) in the U.S.¹ But why is it the top choice?

Tune into a 60-minute live webinar where Drs. Matt Ashley, Raj Shinghal, and Steven Kaplan will distill new and recently published clinical data on the UroLift System. What you can expect to learn during the live webinar:

• UroLift System procedure safety compared to other BPH procedures: an FDA MAUDE-based analysis²
• How newly published, real-world healthcare claims and utilization analysis debunks speculation about durability and helps physicians provide clarity on what patients can expect from minimally invasive and traditional, more invasive BPH procedures³
• The importance of patient experience as a primary consideration when counseling patients about BPH treatment options

Plus, don’t miss the live Q&A session when we will address your questions in real time.

References: 1. U.S. 2022 estimates based on US Market Model 2022-24 (5-17-22 FINAL), which is in part based on Symphony Health PatientSource® 2018-21, as is and with no representations/warranties, including accuracy or completeness; 2. Shinghal R, Ashley M, Eure G (2023). Total Procedural Context is Crucial in Understanding BPH Treatment Device Safety in the FDA’s MAUDE Database. (Manuscript in preparation); 3. Kaplan, Prostate Cancer Prostatic Dis 2023; 4. Roehrborn, J Urology 2013

Consult the Instructions for Use (IFU) for more information. Rx Only.